The announcement of superior immunogenicity and longer duration of immune response of Arcturus Therapeutics' sa-mRNA COVID-19 vaccine compared to first-generation mRNA vaccines, coupled with its recent regulatory approval in Japan, is likely to positively impact investor sentiment. This could lead to increased investor confidence in ARCT's product pipeline and potential revenue growth from the vaccine, thus potentially driving the stock price up in the short term.